Form 4: Intellia Therapeutics EVP, Chief Scientific Officer Laura Sepp-Lorenzino Reports Stock and Option Transactions

Laura Sepp-Lorenzino, EVP and Chief Scientific Officer of Intellia Therapeutics, reports the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

Summary

• On March 1, 2024, Laura Sepp-Lorenzino, EVP and Chief Scientific Officer of Intellia Therapeutics, acquired 37,966 shares of common stock at $0 and disposed of 81,893 shares.
• Following these transactions, Sepp-Lorenzino beneficially owns 81,893 shares of Intellia common stock.
• On the same date, Sepp-Lorenzino also acquired options to purchase 54,794 shares of common stock at an exercise price of $32.66, expiring on February 28, 2034.
• The options vest in installments, with 33% vesting on January 1, 2025, and the remaining 67% vesting monthly thereafter.
• Following the transaction, Sepp-Lorenzino directly owns 54,794 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company executive, with no inherent positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities in the company's stock.

Stakeholder Impact

• The transactions may be of interest to shareholders as they provide insight into the actions of a key executive.

Key Dates